Converting proven injectable biologics into targeted oral therapies for the colon. Better outcomes, lower costs, broader access.
Current injectable biologics deliver less than 5% of their dose to the intestinal target, flooding the body with active drug that causes dose-limiting systemic side effects.
Patients with IBD, colorectal cancer, and rare GI diseases need therapies that act locally, not systemically. Yet the pharmaceutical industry continues to rely on injections because oral delivery of large molecules was considered impossible.
Plantibodies changes that equation with a plant-based bioencapsulation system that protects biologics through the stomach and releases them precisely in the colon.
"What is lacking today is the ability to deliver an effective and safe biological payload at the GI tract level."
Alexandre Lebeaut, MD — Former CSO, Ipsen
From gene to gut. A proprietary system built on 20+ years of plant pharmaceutical science and 6+ years of development at Sorbonne Université.
Focused on GI diseases where local delivery can transform the standard of care.
No fermentation tanks, no chromatographic purification, no mammalian cell culture. Plants grow in greenhouses with sunlight and water. The result: biologics at a fraction of the cost.
Freeze-dried plant cells remain stable at ambient temperature for over 30 months. No cold chain required, enabling distribution to any geography without specialized logistics.
Drug is released precisely in the colon with minimal systemic absorption. This means higher local efficacy and dramatically reduced systemic toxicity compared to injections.
Our platform is grounded in two decades of peer-reviewed research in plant-based pharmaceutical systems.
Leading Plantibodies' vision to transform GI therapeutics through oral biologic delivery. Driving strategy, fundraising, and partnerships.
Heading the scientific platform with 6+ years of research in plant molecular pharming at Sorbonne Université. Overseeing preclinical development and IP strategy.
Partner with Plantibodies to bring oral biologic therapies to patients with GI diseases.
Leverage our platform to convert your injectable biologics into oral formulations. Maintain your IP while accessing a differentiated delivery system for GI indications.
Biologics too toxic for systemic delivery may find new life as local GI therapeutics. Our platform minimizes systemic exposure, enabling a second chance for promising molecules.
Add oral biologic candidates to your portfolio. Our technology is compatible with monoclonal antibodies, cytokines, enzymes, and peptides from small (<20 kDa) to large (250 kDa).
67 rue Saint-Jacques
75005 Paris, France
Sorbonne Université, Paris
Molecular & plant biology, vertical farming
